Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daptomycin for MSSA bacteremia
NCT02972983Phase 4Completed
- Sponsor
- McGill University Health Centre
- Start
- Dec 2016
- Primary completion
- Jul 2019
- Modality
- Cyclic Peptides, Antimicrobial Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in Staphylococcus aureus bacteremia (SAB) comparing Daptomycin with Placebo (2 arms). Primary endpoint: Blood culture clearance at 5 days. Started Dec 2016; status: completed.
02
Drugs
daptomycin
03
Conditions
Staphylococcus aureus bacteremia (SAB)
Beyond the preview
Go deeper on NCT02972983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02972983.